Molecular markers of pituitary tumor development, progression and therapy response
Project Title: „Molecular markers of pituitary tumor development, progression and therapy response”
Funding: European Regional Development Fund (ERDF), Measure 126.96.36.199 “Industry-Driven Research”
Project Nr.: 188.8.131.52/16/A/066
Period: 1st January 2017 – 31 st December 2019
Project costs: 648 600,28 EUR
Principle Investigator: Dr. biol., Assoc. Prof. J. Kloviņš
Pituitary adenomas are rare benign tumors that are responsible for serious health complications with increased morbidity and mortality. Despite the extensive studies the primary genetic defects determining the tumorigenesis of pituitary adenomas is still unclear and very heterogeneous. Another problem is the inaccessibility of the pituitary gland that hampers the use of molecular biomarkers for observation or differential treatment purpose. Accordingly, to successfully treat pituitary adenomas more rigorous diagnostic approaches are needed that would allow for detailed tumor subtype classification to enable personalized treatments. The project is aimed to help in solving these issues. The main objective of this project is to investigate molecular determinants of pituitary adenoma development and progression and to identify the crucial factors linked to variability in clinical outcome that could further be applied as biomarkers for improvement of pituitary tumor treatment therapies. Specifically we aim (1) to identify disease specific somatic genetic variations in different types of pituitary adenoma and use this information to characterize the separate cell populations in adenoma resections as well as markers for non-invasive monitoring of adenomas, (2) to identify vesicle associated based RNA markers that differentiate between healthy subjects and pituitary adenoma patients, as well as different clinical outcomes and treatment efficiency, (3) to estimate the best combination of variable biomarkers that can predict PA growth dynamics and recurrence probability. Presented project will perform original and innovative experiments including the genetic characterization of the tumor specific cell populations, estimation of tumor specific cell free DNA and identification of vesicle associated RNA as liquid biopsy based biomarkers that has not been done in case of pituitary adenoma studies.
Information published: 02.01.2017.